WestEnd Advisors’s GSK GSK Stock Holding History

WestEnd Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-56	Closed	-$2.99K	–	67
2019 Q3	$2.99K	Buy	+56	New	+$2.88K	﹤0.01%	53

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

WestEnd Advisors's GSK Position: Q4 2019 in Review

WestEnd Advisors sold out of GSK (GSK) in Q4 2019, closing a stake of 56 shares — an estimated $2.99K sold.

WestEnd Advisors first reported a position in GSK in Q3 2019 and held it in 1 quarter. The position peaked at $2.99K in Q3 2019. 894 funds tracked by Wall St. Rank hold GSK as of Q4 2019.

WestEnd Advisors reported no remaining GSK position as of Q4 2019 after selling out during the quarter.
WestEnd Advisors sold 56 GSK shares in Q4 2019, an estimated $2.99K.
WestEnd Advisors first reported a position in GSK in Q3 2019 and held it in 1 quarter.
WestEnd Advisors's GSK position peaked at $2.99K in Q3 2019.
894 funds tracked by Wall St. Rank held GSK as of Q4 2019.

Based on WestEnd Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.